INVESTORS

Building a Scalable
AI Platform for Earlier
Disease Risk Identification

Explore ALZAI Health’s investor information, including corporate updates,
financial reports, regulatory filings and key developments as we advance our
AI-driven healthcare platform.

ABOUT ALZAI HEALTH

Turning Existing Healthcare Data Into Disease-Specific Risk Intelligence

ALZAI Health is developing a scalable AI platform that uses routine healthcare data to identify individuals at elevated disease risk before traditional diagnosis. With proprietary models for brain and liver health, the platform supports earlier risk identification across clinical trials, pharmaceutical development, health plans, health systems and preventive healthcare, with the potential to expand into additional diseases.

Highlights

0 M+
Patient Records in
Alzheimer’s Validation*
0 M+
U.S. Patient Records
0 M+
Patient Records
in Liver Validation*
Up to 0 Years
Prediction Horizon*
0 +
Clinical Biomarkers Analyzed

Chart

Profile

Alzai Health Corp.
22 Adelaide St. West, Suite 3400,
Toronto, Ontario, M5H 4E3, Canada
Tel: +1 (416) 862-4351
Email: hayim@alzaihealth.com or roy@alzaihealth.com
Website: www.alzaihealth.com
Date of Formation:
November 15, 2024
Exchange/Ticker:
TSX-V: ALZI
Jurisdiction Where Formed:
Ontario, Canada
Financial Year End:
April 30
CUSIP:
02262P103
ISIN:
02262P1036
Industry Classification:
R&D in the physical, engineering and life sciences
Transfer Agent:
Odyssey Trust Company
Auditors:
Davidson & Company LLP

SEDAR+ Listing

Visit SEDAR+ to search the System for Electronic Document Analysis and Retrieval to view company documents.

Investor Relations

SEND US A MESSAGE

This field is for validation purposes and should be left unchanged.